Thursday, March 8, 2012

XMetA by Bhaskar at XOMA

XMetA is the first antibody specific for the insulin receptor shown to correct hyperglycemia in a mouse model of diabetes. Results of a study conducted by XOMA and confirmed by investigators at the University of California, San Francisco, demonstrate that XMetA has the potential to be a novel, long-acting agent for the control of blood glucose levels in patients with diabetes.
The study by Bhaskar, et al. demonstrated that XMetA markedly reduced elevated fasting blood glucose levels and normalized glucose tolerance in mice experimentally rendered diabetic. After six weeks of treatment, there was a statistically significant reduction in hemoglobin A1c levels in animals treated with XMetA compared to controls (p < 0.05). In addition, elevated non-HDL cholesterol levels were improved relative to control mice (p < 0.05). Hypoglycemia and weight gain were not observed during this study, nor was proliferation of cell growth.


Press Release: http://www.sciencecodex.com/first_allosteric_insulin_receptoractivating_antibody_to_improve_glycemic_control_in_vivo-87483
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Bhaskar%20XMetA

No comments:

Post a Comment